MedTrace Logo

tACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex

NCT07240272 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-11-20

No results posted yet for this study

Summary

This clinical trial aims to study whether transcranial alternating current stimulation (tACS) applied to the medial frontal cortex (MFC) can improve speech and cognitive function in people with Parkinson's disease (PD), and to evaluate the safety of tACS. The main goals are to answer the following questions:

1. Can tACS stimulation of the MFC improve executive functions in people with PD (such as reasoning, planning, inhibition, and complex problem-solving)?
2. Can it improve the integration of auditory information and speech motor control during communication?

Researchers will compare the effects of real tACS versus sham (placebo) stimulation to see if real stimulation leads to better speech and cognitive outcomes in PD patients.

Participants will:

1. Receive one extra 20-minute session of either real or sham tACS each day for two weeks
2. Attend clinic visits before stimulation, right after the 2-week period, and again at 1 month and 3 months for assessments and tests
3. Have their executive function scores, speech performance, and related brain activity recorded

Conditions

  • Parkinson Disease

Interventions

OTHER

6Hz-tACS

tACS applied to the MFC at a frequency of 6 Hz, using a high-definition 1×4 electrode configuration with individualized current intensity, delivered for 20 minutes.

OTHER

Sham-tACS

Except for turning down the current intensity to zero during the 20-minute period, all other parameters are identical to those in 6Hz-group.

Sponsors & Collaborators

  • Ke Dong, MD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-05-01
Completion
2025-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240272 on ClinicalTrials.gov